Stereotaxis, Inc. (STXS) Q1 2025 Earnings Call

Concluded May 12, 2025

May 12, 2025 0 turns

Period: FY2025 Q1
Runtime: —
Sources: 2 artifacts

Revenue $7.47M +8.6% YoY

Diluted EPS -$0.07

Gross margin 54.4% -3.2 pp YoY

Net income -$5.82M

Open full screen 8-K 10-Q

Executive readout · one minute

Webcast research workspace

Read the call alongside every captured source. 8-K earnings release, 10-Q stay in one workspace.

Regulatory approvals for new product ecosystem 63 Johnson & Johnson legacy transition headwinds 21 Genesis X capital system launch 19 PFA (pulsed field ablation) development 17 Synchrony digital surgery cockpit 14 Vision and long-term endovascular robotics opportunity 13

Management tone

Confident

Net tone +78 · low hedging

Grounding quotes

“Stereotaxis has had an amazing start to this year. While our reported quarterly numbers don't yet reflect it, we're going through one of the most exciting periods in Stereotaxis' history”
“The structural transformation to our disposable business model is taking place as we simultaneously structurally transform our capital business”
“We're very confident in our guidance of $3 million in revenue from Synchrony this year”
“The initial commercial green shoots from our new product portfolio are exciting”

Research coverage

2 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

8-K earnings release Filed May 12, 2025 10-Q report Filed May 13, 2025 Company webcastOpen the original investor-relations page

Quarter detail

How the reported period landed and where the business moved.

Revenue · products & services

Disposables Service and Accessories$5.51M +29.1% YoY

Systems$1.96M -24.8% YoY

Read transcripts like this one from Claude, ChatGPT or your own code with the earnings call transcript API →